Víctor Alfonso Jiménez Díaz: SAPT or DAPT in Valve-in-Valve TAVI? Walking a Fine Line
Víctor Alfonso Jiménez Díaz, Director, Cardiovascular Research Unit, Hospital Álvaro Cunqueiro at Hospital Álvaro Cunqueiro, University Hospital Complex of Vigo, shared a post on LinkedIn:
“SAPT or DAPT in Valve-in-Valve TAVI? Walking a Fine Line
Antithrombotic therapy after TAVI remains one of the most complex challenges in structural heart interventions. Although the POPular TAVI trial shifted the balance toward single antiplatelet therapy (SAPT) in the general population, can we apply the same logic to Valve-in-Valve (ViV) procedures?
We have just published our editorial comment in JACC: Cardiovascular Interventions: “Still Walking a Fine Line,” where we analyze the interesting study by Bendandi et al. on the use of SAPT vs. DAPT in ViV procedures.
Why is the ViV scenario different?
-In ViV, altered anatomy and hemodynamic limitations can amplify thrombotic risk.
-Evidence from native TAVI is not always extrapolable to patients with failed bioprostheses.
-The balance between bleeding risk and leaflet thrombosis is, now more than ever, a “fine line.”
This editorial highlights the urgent need for subgroup-specific data and individualized decision-making.
Congratulations to my colleague Cláudio Espada Guerreiro for this analysis and to Francesco Bendandi, Palmerini Tullio, Federico De Marco, Cosmo Godino, Chiara Fraccaro, Marco Barbanti, francesco maisano, Francesco Saia and the entire Italian team for the original research.
Read the full editorial here”
Title: Dual vs Single Antiplatelet Therapy After Valve-in-Valve TAVR: Still Walking a Fine Line
Authors: Victor Alfonso Jimenez Diaz, Claudio Guerreiro
Get the latest updates with Hemostasis Today.
-
Jul 19, 2026, 16:59Rupam Manna: Not All Portal Vein Involvement in HCC Is the Same
-
Jul 19, 2026, 16:58Axel Cangas: Exploring the Future of Hemophilia Care at ISTH 2026
-
Jul 19, 2026, 16:58Aviva Schwartz: Air Pollution and Women’s Hematological Health in the Spotlight at ISTH 2026
-
Jul 19, 2026, 16:56Lola Sepot-Boucherit: Reimagining the Future of Rare Bleeding Disorders at ISTH 2026
-
Jul 19, 2026, 16:54Belén de la Morena Barrio: Presenting Our Research on Long-Read Sequencing for Genetic Diagnosis at ISTH 2026
-
Jul 19, 2026, 16:52Shamee Shastry: Sometimes the Answer is Not in the Test Tube Alone, but at the Patient’s Bedside
-
Jul 19, 2026, 16:52Manuela Albisetti: Congratulations to Alessandra Bosch on an Outstanding ISTH 2026 Talk
-
Jul 19, 2026, 16:44Fernanda Orsi: A Memorable Week of Science and Collaboration at ISTH 2026
-
Jul 19, 2026, 16:37William Aird: A Visual Guide to Understanding von Willebrand Disease